SAN DIEGO -- Both fixed and flexible doses of investigational tavapadon met their primary endpoint in phase III trials of early Parkinson's disease. In the TEMPO-1 (fixed dose) and TEMPO-2 (flexible ...
Buntanetap showed dose-dependent and statistically significant improvements in cognition in the overall enrolled PD population. Parkinson’s patients with substantial cognitive decline exhibited a very ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results